| Q40953058 | ACE inhibitors. Differential use in elderly patients with hypertension |
| Q41778874 | Attenuation by ACE inhibitor drugs of alpha-adrenoceptor sensitivity in human vessels: possible differences related to drug lipophilicity |
| Q44603699 | Bioequivalence evaluation of two brands of enalapril 20mg tablets (narapril and renitec) in healthy human volunteers |
| Q40931110 | Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease |
| Q47913024 | Clinical pharmacokinetics of vasodilators. Part I. |
| Q50622756 | Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. |
| Q53977181 | Effect of enalapril and quinapril on forearm vascular ACE in man. |
| Q33573968 | Formulary management of ACE inhibitors |
| Q39781860 | Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. |
| Q59794205 | Pharmacokinetics of Toxin-Derived Peptide Drugs |
| Q44551442 | Phenyramidol-associated liver toxicity |
| Q40395221 | Quinapril. A reappraisal of its pharmacology and therapeutic efficacy in cardiovascular disorders |
| Q34511006 | Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders |
| Q33504342 | Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application |
| Q36066647 | The role of human carboxylesterases in drug metabolism: have we overlooked their importance? |
| Q73097609 | Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations |